Key result
Chronic PDE5 inhibition significantly reduces pulmonary pressures and pulmonary vascular resistance, and improves exercise capacity in selected patients with LVSD and pulmonary hypertension.
Why the study?
Does phosphodiesterase type 5 (PDE5) inhibition improve outcomes in patients with pulmonary hypertension and left ventricular systolic dysfunction?
Population
Patients with pulmonary hypertension and right ventricular failure in left ventricular systolic dysfunction
Design
Review
Authors
Loading...
May support PDE5 inhibition in selected LVSD-PH cases; leaves open need for RCTs on hard outcomes.
Does phosphodiesterase type 5 (PDE5) inhibition improve outcomes in patients with pulmonary hypertension and left ventricular systolic dysfunction?
Chronic PDE5 inhibition may be a beneficial therapeutic option for carefully selected patients with LVSD and persistent pulmonary hypertension or uncontrolled RVF despite standard therapies.
Thomas G. Di Salvo (2012) conducted a review in Pulmonary hypertension and right ventricular failure in left ventricular systolic dysfunction. Phosphodiesterase type 5 (PDE5) inhibition was evaluated. Chronic PDE5 inhibition significantly reduces pulmonary pressures and pulmonary vascular resistance, and improves exercise capacity in selected patients with LVSD and pulmonary hypertension.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: